Eribulin in patients with hepatic or renal impairment
Pharmacokinetic studies of eribulin show that drug exposure is greater in patients with hepatic impairment or severely impaired renal function [1561]. Therefore, eribulin dose adjustments may be required for mBC patients with hepatic and renal impairment. Eribulin should be used with caution and at the discretion of the treating physician in such patients. The recommended doses of eribulin in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment are 1.1 and 0.7 mg/m2, respectively [61]. Eribulin has not been studied in patients with severe hepatic impairment (Child-Pugh C), but it is expected that a more significant dose reduction ma y be needed if eribulin is used in these patients. Patients with impaired renal function may also require a dose reduction although the optimal dose for this patient group remains to be established.